Mads Nikolaj Behrndt-Eriksen
CIK: 0002128919
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
COAG
Hemab Therapeutics Holdings, Inc.
Officer
Discretionary Trading P&L
Holdings
About Behrndt-Eriksen Mads Nikolaj
Behrndt-Eriksen Mads Nikolaj (SEC CIK 0002128919) files insider reports with the SEC as Officer of Hemab Therapeutics Holdings, Inc. (COAG).
Signal8 holds 1 ownership filing by Behrndt-Eriksen Mads Nikolaj, a Form 4, filed on May 4, 2026. Those filings report 2 transactions, from Jan 29, 2026 to Apr 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Behrndt-Eriksen Mads Nikolaj's filings is in CAMBRIDGE, MA.
Recent filings by Behrndt-Eriksen Mads Nikolaj
Other insiders filing for Hemab Therapeutics Holdings, Inc. (COAG)
- Walbert Keli, Director
- RA CAPITAL MANAGEMENT, L.P., 10% Owner
- AI DEN-MAB LLC, 10% Owner
- Novo Holdings A/S, 10% Owner
- MARAGANORE JOHN, Director
- Madigan Catherine, Chief Medical Officer